SG11201908337VA - Stimulatory cell lines for ex vivo expansion and activation of natural killer cells - Google Patents

Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Info

Publication number
SG11201908337VA
SG11201908337VA SG11201908337VA SG11201908337VA SG 11201908337V A SG11201908337V A SG 11201908337VA SG 11201908337V A SG11201908337V A SG 11201908337VA SG 11201908337V A SG11201908337V A SG 11201908337VA
Authority
SG
Singapore
Prior art keywords
singapore
international
activation
cell lines
cells
Prior art date
Application number
Other languages
English (en)
Inventor
Takahiro Kamiya
Dario Campana
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG11201908337VA publication Critical patent/SG11201908337VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201908337V 2017-03-27 2018-03-27 Stimulatory cell lines for ex vivo expansion and activation of natural killer cells SG11201908337VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477311P 2017-03-27 2017-03-27
PCT/SG2018/050138 WO2018182511A1 (en) 2017-03-27 2018-03-27 Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Publications (1)

Publication Number Publication Date
SG11201908337VA true SG11201908337VA (en) 2019-10-30

Family

ID=63676404

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908337V SG11201908337VA (en) 2017-03-27 2018-03-27 Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Country Status (13)

Country Link
US (1) US11896616B2 (enExample)
EP (1) EP3601537A4 (enExample)
JP (1) JP7270253B2 (enExample)
KR (1) KR102624509B1 (enExample)
CN (1) CN110494557A (enExample)
AU (1) AU2018245749A1 (enExample)
BR (1) BR112019020001A2 (enExample)
CA (1) CA3056591A1 (enExample)
IL (1) IL269380A (enExample)
MX (1) MX2019011570A (enExample)
RU (1) RU2019128544A (enExample)
SG (1) SG11201908337VA (enExample)
WO (1) WO2018182511A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN113710691B (zh) * 2019-02-20 2025-03-04 罗格斯新泽西州立大学 自然杀伤和嵌合抗原受体修饰的细胞的扩增
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
AU2020321354A1 (en) * 2019-07-31 2022-03-03 Nkarta, Inc. Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
EP4163367A4 (en) * 2020-06-09 2024-06-26 Samsung Life Public Welfare Foundation GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
KR102596913B1 (ko) * 2020-06-09 2023-11-02 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도
WO2021251707A1 (ko) * 2020-06-09 2021-12-16 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도
KR20230084470A (ko) * 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
IL300903A (en) * 2020-09-02 2023-04-01 Nkarta Inc Expansion and enhanced cytotoxicity of natural killer cells and their uses
CN112553165A (zh) * 2020-12-11 2021-03-26 北京双因生物科技有限公司 以修饰的msc培养nk细胞的方法
CN112501127B (zh) * 2020-12-21 2023-10-10 广东昭泰细胞生物科技有限公司 一种重编程nk细胞的培养方法
CN116801902A (zh) * 2021-01-19 2023-09-22 黑曜石疗法公司 具有膜结合白细胞介素15的肿瘤浸润淋巴细胞及其用途
JP7893814B2 (ja) * 2021-01-19 2026-07-22 オブシディアン セラピューティクス， インコーポレイテッド Ｔ細胞及び腫瘍浸潤リンパ球の拡張のための組成物及び方法
CN112941032A (zh) * 2021-02-23 2021-06-11 北京双因生物科技有限公司 以修饰的msc培养记忆型t细胞的方法
CN117701578A (zh) * 2022-09-14 2024-03-15 江苏普瑞康生物医药科技有限公司 用于扩增nk细胞的rna组合物及基于其的基因修饰nk细胞药物制剂
KR102669705B1 (ko) * 2023-02-24 2024-06-10 이엔셀 주식회사 제대혈 유래 자연 살해 세포의 확장배양방법
KR20240175366A (ko) * 2023-06-12 2024-12-20 한국화학연구원 Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도
CN118291378A (zh) * 2024-04-08 2024-07-05 上海泓纯生物科技工程有限公司 培养混合免疫细胞的组合物和混合免疫细胞培养方法
CN119464219A (zh) * 2024-11-18 2025-02-18 百吉生物医药(广州)股份有限公司 一种扩增nk细胞的饲养细胞及其制备方法和应用
CN120082512B (zh) * 2025-03-13 2026-02-03 广东众合天诚生物科技有限公司 一种诱导性nk细胞的培养方法

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
AU6827094A (en) 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US5653977A (en) 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US20020018783A1 (en) 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
ATE264911T1 (de) 1998-02-02 2004-05-15 Univ Johns Hopkins Med Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
WO1999067360A2 (en) 1998-06-25 1999-12-29 Hemosol Inc. Media and methods for expansion of erythroid stem cells for the production of hemoglobin
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
JP3619853B2 (ja) 1999-11-26 2005-02-16 独立行政法人理化学研究所 ナチュラルキラー細胞の増殖方法
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
KR100888915B1 (ko) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
JP2004538331A (ja) 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
CA2483343A1 (en) 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7740871B2 (en) 2002-09-19 2010-06-22 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
GB0225279D0 (en) 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2530349A1 (en) 2003-06-27 2005-01-06 Dnavec Research Inc. Method for transplanting lymphohematopoietic cells into mammal
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
ES2678094T3 (es) 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
GB0426903D0 (en) 2004-12-08 2005-01-12 Alexis Biotech Ltd Complexes and methods
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US20110059137A1 (en) 2008-03-21 2011-03-10 H. Lee Moffitt Cancer Center And Research Institutute, Inc Chemokine gene-modified cells for cancer immunotherapy
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
WO2010071836A1 (en) 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
JP2012521215A (ja) 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Ｎｋ細胞の増殖
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
EP2493486A1 (en) 2009-10-30 2012-09-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011053321A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20130011376A1 (en) 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
WO2011150976A1 (en) 2010-06-04 2011-12-08 bioMérieux Method and kit for the prognosis of colorectal cancer
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
EP2407531A1 (en) 2010-07-16 2012-01-18 Neste Oil Oyj Microorganisms with extended substrate utilization range
WO2012136231A1 (en) 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
CA2818684C (en) 2010-11-22 2023-02-21 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
AU2011377617B2 (en) 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
ITMO20110270A1 (it) 2011-10-25 2013-04-26 Sara Caldrer Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
CN103294374A (zh) 2012-02-23 2013-09-11 中兴通讯股份有限公司 一种触摸屏解锁方法及装置
CN102637127B (zh) 2012-02-24 2015-04-08 青岛海信电器股份有限公司 一种控制鼠标模块的方法及电子设备
DK3578201T3 (da) 2012-06-28 2023-05-08 Univ Of Central Florida Research Foundation Incorporated Fremgangsmåder og sammensætninger til naturlige dræberceller
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US10626463B2 (en) 2012-08-03 2020-04-21 Icahn School Of Medicine At Mount Sinai Biomarker associated with risk of melanoma reoccurrence
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10786532B2 (en) 2012-10-02 2020-09-29 Versiti Blood Research Institute Foundation, Inc. Method of providing cellular therapy using modified natural killer cells or T lymphocytes
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
CN103113470B (zh) 2013-02-27 2015-04-22 四川大学 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
CN105339498A (zh) 2013-03-07 2016-02-17 贝勒医学院 癌症中靶向cd138
HK1220614A1 (zh) 2013-03-10 2017-05-12 Baylor College Of Medicine 耐化疗免疫细胞
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
AU2014386824B2 (en) 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
US20160250258A1 (en) 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
CN106414723A (zh) 2014-02-10 2017-02-15 纳维基因股份有限公司 细胞调节纳米组合物及使用方法
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
WO2015164759A2 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Mnd promoter chimeric antigen receptors
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
RS61406B1 (sr) 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
WO2016040441A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
PT3575315T (pt) 2014-09-15 2022-12-16 Agc Biologics S P A Recetores de antigénios quiméricos
WO2016042041A1 (en) 2014-09-16 2016-03-24 Fundacion Publica Andaluza Progreso Y Salud USE OF CORD BLOOD PLASMA TO TREAT NK CELL-MEDIATED DISEASES AND IFN-γ MEDIATED DISEASES
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
AU2015339447B2 (en) 2014-10-27 2021-08-12 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
RU2017125531A (ru) 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
KR20230146101A (ko) 2014-12-31 2023-10-18 안트로제네시스 코포레이션 천연 킬러 세포 및 그의 용도
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
EP3247368A4 (en) 2015-01-23 2019-01-02 Musc Foundation for Research Development Cytokine receptor genes and the use thereof to enhance therapy
MA41433A (fr) 2015-01-26 2017-12-05 Baylor College Medicine Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
CN113862292B (zh) 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
US20190024065A1 (en) 2015-02-06 2019-01-24 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN107708710A (zh) 2015-03-17 2018-02-16 嵌合体生物工程公司 Smart CAR装置,DE CAR多肽,Side CAR及其使用
EP3270960A4 (en) 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
CN108367057B (zh) 2015-04-06 2022-11-22 赛通免疫股份有限公司 用于胶质母细胞瘤的egfr导向的car疗法
WO2016172537A1 (en) 2015-04-23 2016-10-27 The Trustees Of The University Of Pennsylvania Compositions to disrupt protein kinase a anchoring and uses thereof
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507104D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US11534460B2 (en) 2015-05-11 2022-12-27 University Health Network Method for expansion of double negative regulatory T cells
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR20230005428A (ko) 2015-05-28 2023-01-09 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
WO2016197108A1 (en) 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
ES2958720T3 (es) 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
JP6556523B2 (ja) 2015-06-24 2019-08-07 株式会社やまびこ 層状掃気式２サイクル内燃エンジン用のエアクリーナ
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
MX2018000278A (es) 2015-06-29 2018-03-08 Univ Johns Hopkins Terapia de receptores quimericos de puntos de control inmunitarios.
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
WO2017023859A1 (en) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
HUE067376T2 (hu) 2015-08-04 2024-10-28 Xyphos Biosciences Inc Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
JP6894430B2 (ja) 2015-08-24 2021-06-30 セレクティスＣｅｌｌｅｃｔｉｓ 統合された制御機能を有するキメラ抗原受容体
EP3138905A1 (en) 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
US20180291080A1 (en) 2015-09-28 2018-10-11 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
ES2909973T3 (es) 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
CN107109363A (zh) 2015-11-09 2017-08-29 张明杰 增强对异常细胞杀伤力的方法和药物组合物
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
JP6853514B2 (ja) 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
CN110358736B (zh) 2016-05-20 2023-07-07 杭州朔溪生物医药有限公司 一种修饰的k562细胞、其制备方法及nk细胞培养组合物
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
CN105985931A (zh) 2016-06-21 2016-10-05 黑龙江天晴干细胞股份有限公司 一种nk细胞体外扩增组合物及nk细胞扩增方法
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
CN109554348A (zh) 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 可诱导分泌抗cd47抗体的工程化免疫细胞
WO2019077037A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY
CN107827990B (zh) 2017-10-30 2020-07-10 河北森朗生物科技有限公司 一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
WO2019127215A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN109971712B (zh) 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
SG11202007183PA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN111088231A (zh) 2018-10-24 2020-05-01 艾生命序公司 Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
AU2020315213A1 (en) 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells

Also Published As

Publication number Publication date
RU2019128544A (ru) 2021-04-28
EP3601537A1 (en) 2020-02-05
US20200016208A1 (en) 2020-01-16
JP2020516238A (ja) 2020-06-11
MX2019011570A (es) 2019-11-18
KR20190133732A (ko) 2019-12-03
KR102624509B1 (ko) 2024-01-12
EP3601537A4 (en) 2021-01-13
BR112019020001A2 (pt) 2020-04-28
IL269380A (en) 2019-11-28
RU2019128544A3 (enExample) 2021-12-14
CN110494557A (zh) 2019-11-22
US11896616B2 (en) 2024-02-13
CA3056591A1 (en) 2018-10-04
AU2018245749A1 (en) 2019-10-03
JP7270253B2 (ja) 2023-05-10
WO2018182511A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201908796XA (en) Improved antigen binding receptors
SG11201909931PA (en) Oligomeric particle reagents and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201907319QA (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201807300PA (en) Uterine cancer treatments
SG11201811048UA (en) Single-cell transcript sequencing
SG11201906717SA (en) Methods and systems for associating physical and genetic properties of biological particles
SG11201808797XA (en) T cell receptors
SG11201807444PA (en) Transposase-mediated imaging of the accessible genome
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201908492PA (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201908658TA (en) Nucleobase editors comprising nucleic acid programmable dna binding proteins
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201805835WA (en) Modified oncolytic virus